REGENXBIO ($RGNX) posted quarterly earnings results for Q1 2026 on Thursday, May 14th. The company reported earnings of -$1.72 per share, missing estimates of -$1.37 by $0.35. The company also reported revenue of $6,390,000, missing estimates of $26,848,440 by $-20,458,440.
You can see Quiver Quantitative's $RGNX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
REGENXBIO Insider Trading Activity
REGENXBIO insiders have traded $RGNX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $RGNX stock by insiders over the last 6 months:
- STEVE PAKOLA (Chief Medical Officer) has made 0 purchases and 2 sales selling 20,433 shares for an estimated $221,738.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
REGENXBIO Hedge Fund Activity
We have seen 85 institutional investors add shares of REGENXBIO stock to their portfolio, and 81 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO removed 483,746 shares (-12.0%) from their portfolio in Q4 2025, for an estimated $6,965,942
- INVENOMIC CAPITAL MANAGEMENT LP removed 426,904 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $6,147,417
- ACADIAN ASSET MANAGEMENT LLC removed 372,166 shares (-99.1%) from their portfolio in Q1 2026, for an estimated $3,118,751
- REDMILE GROUP, LLC removed 324,585 shares (-6.9%) from their portfolio in Q4 2025, for an estimated $4,674,024
- MORGAN STANLEY added 310,520 shares (+18.2%) to their portfolio in Q4 2025, for an estimated $4,471,488
- STATE STREET CORP added 301,858 shares (+15.2%) to their portfolio in Q4 2025, for an estimated $4,346,755
- VOSS CAPITAL, LP removed 280,000 shares (-48.7%) from their portfolio in Q4 2025, for an estimated $4,032,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
REGENXBIO Analyst Ratings
Wall Street analysts have issued reports on $RGNX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 12/19/2025
- Chardan Capital issued a "Buy" rating on 11/20/2025
To track analyst ratings and price targets for REGENXBIO, check out Quiver Quantitative's $RGNX forecast page.
REGENXBIO Price Targets
Multiple analysts have issued price targets for $RGNX recently. We have seen 6 analysts offer price targets for $RGNX in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Yi Chen from HC Wainwright & Co. set a target price of $30.0 on 03/09/2026
- Judah Frommer from Morgan Stanley set a target price of $17.0 on 03/06/2026
- Daniil Gataulin from Chardan Capital set a target price of $50.0 on 02/10/2026
- Paul Choi from Goldman Sachs set a target price of $12.0 on 02/10/2026
- Annabel Samimy from Stifel set a target price of $45.0 on 12/19/2025
- Mani Foroohar from Leerink Partners set a target price of $20.0 on 12/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
